ライフサイエンスコーパス: cross-over study

1 ) participated in this randomized controlled cross-over study.

2 s) in this double-blind, placebo controlled, cross-over study.

3 mputees who had TMR in a balanced randomized cross-over study.

4 d, double-blinded, placebo-controlled, 2-way cross-over study.

5 healthy males participated in the randomized cross-over study.

6 ed, double-blind, placebo-controlled, triple cross-over study.

7 ticipated in this double-blinded, randomized cross-over study.

8 hy volunteers in a randomized, double blind, cross-over study.

9 ry of weight loss in a 12-month, randomized, cross-over study.

10 andomized, double-blind, placebo-controlled, cross-over study.

11 In a single-blind, cross-over study, 10 trained cyclists (age 29 +/- 6 year

12 In this double-blind, randomized, cross-over study, 169 cannabis users, aged 18-55 years,

13 In a double-blind, randomized, cross-over study, 30 healthy men were exposed to diluted

14 In this multisite randomized single-blind cross-over study, 44 patients (mean age, 49 +/- 10 years

15 In a randomized cross-over study, 45 participants visited the lab twice,

16 y, placebo- and active-controlled, phase IIa cross-over study, 53 participants were randomized to JNJ

17 bel, single-center, prospective, randomized, cross-over study and compared steady-state pharmacokinet

18 s double-blind, randomized, counterbalanced, cross-over study assessed the neural response to social

19 randomized, double-blind, placebo-controlled cross-over study assessing the effect of inhaled inorgan

20 A cross-over study assessing the function of male PVAT on

21 three separate but complementary open-label cross-over studies comparing no medication with aciclovi

22 andomized, double-blind, placebo-controlled, cross-over study design (two sessions per participant; 1

23 A cross-over study design evaluated appointment adherence

24 Using a four-period randomized cross-over study design, 14 beagles were challenged with

25 Employing a human cross-over study design, we demonstrate that distinct ma

26 thy participants were tested in a randomized cross-over study design.

27 kly alendronate or placebo in a double-blind cross-over study designed to assess the safety and effic

28 In this double-blind cross-over study, each subject was exposed to both activ

29 This double-blind cross-over study evaluated patient preference for pazopa

30 ed, controlled, examiner-masked, four-period cross-over study examined plaque removal with the two to

31 a single-blind, randomised, sham-controlled, cross-over study for 10 nights, sleeping when exposed to

32 ular health were assessed in two controlled, cross-over studies in free-living normocholesterolemic a

33 A randomized, double blind, cross-over study in 12 HS and 12 GERD patients pre-treat

34 ouble-blind, randomized, placebo-controlled, cross-over study in 25 healthy participants.

35 performed a 5-day, prospective, randomized, cross-over study in a French mood disorder unit for inpa

36 We conducted a double-blind, randomized, cross-over study in adults, aged 18-55 years, who use ca

37 We performed a single blind, cross-over study involving 12 CD patients who had been o

38 In a randomized, double-blind cross-over study, nondiabetic patients with heart failur

39 In a cross-over study of 15 male and 15 female adults, we fou

40 andomized, double-blind, placebo-controlled, cross-over study of 19 high-functioning adult male subje

41 We performed a 3-period, cross-over study of 29 adult patients with IBS (based on

42 (CAF) can mitigate exposures, we conducted a cross-over study of 48 adults exposed to TRAP during two

43 This is a randomized prospective cross-over study of BE patients undergoing endoscopy who

44 In a prospective cross-over study of IBD patients undergoing surveillance

45 In a controlled, cross-over study of patients with IBS, a diet low in FOD

46 e, conducted a randomized placebo-controlled cross-over study of the effects of 4 wk of continuous po

47 ingle-blind, randomised, placebo controlled, cross-over study of the microcirculatory response to top

48 This single-center, prospective, cross-over study randomized 30 patients with cirrhosis,

49 Cross-over study revealed that consumption of OP-bread s

50 In a cross-over study, six burned children were treated with

51 This double-blind and placebo-controlled cross-over study tested the effects of two separate KME

52 a double-blind, placebo-controlled phase III cross-over study that compared aprepitant to placebo com

53 In a randomized cross-over study, the effect of injectable norethisteron

54 A cross-over study was done in 19 healthy volunteers recei

55 andomised, double blind, placebo-controlled, cross-over study was performed in Cambridge, UK, studyin

56 A randomized, double-blind, cross-over study was performed to compare postprandial p

57 A prospective, randomized, controlled cross-over study was performed to evaluate pharmacodynam

58 ouble-blind, randomised, placebo-controlled, cross-over study was performed, and dynamic causal model

59 ntre, single dose, randomized, double-blind, cross-over study was planned to assess the pharmacokinet

60 randomised, double-blind, placebo-controlled cross-over studies which had similar but not identical d

61 In a randomised, cross-over study with 12 healthy volunteers, the pharmac

62 resonance imaging (phMRI) in a double blind cross-over study with 13 healthy male volunteers.

63 ticus) in a single-center and single-blinded cross-over study with children aged 24-36 months old in

64 mmation, a double-blind, placebo-controlled, cross-over study with inhaled budesonide was conducted i

65 o groups using stratified randomization in a cross-over study with subjects undergoing either 8 plasm

66 We performed a randomized, single-blind, cross-over study, with 2 study visits 4 weeks apart, to